 NEW YORK, Oct. 1, 2021 PRNewswire -- Actinium Pharmaceuticals, Inc. NYSE AMERICAN: ATNM Actinium or the Company, a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that two abstracts featuring targeted radiotherapies in combination with CD47 antibody immunotherapy for solid tumor and hematologic indications have been accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy for Cancer SITC 2021. Actiniums abstract titles and presentation logistics are as follows: Title: Enhancement of the anti-tumor effects of CD47 blockade in solid tumors by combination with targeted radioimmunotherapy Poster Number: 589 Location: Poster Hall Dates and Times: 11122021 - 11142021, 7:00 am - 5:00 pm Title: Anti-CD33 actinium-225 targeted radioimmunotherapy enhances the biologic activity of anti-CD47 antibody immunotherapy in preclinical models of acute myeloid leukemia Poster Number: 590 Location: Poster Hall Dates and Times: 11122021 - 11142021, 7:00 am - 5:00 pm Sandesh Seth, Actiniums Chairman and CEO, said, We are excited to highlight our latest RD efforts focused on combinations of actinium-225 based targeted radiotherapies with CD47 immunotherapies, which has emerged as one of the most active targets in immunotherapy drug development of late, in solid tumors and blood cancers. 